Literature DB >> 3128137

A comparison of oxygen therapy devices used in the postoperative recovery period.

A B Williams1, P L Jones, W W Mapleson.   

Abstract

Seventy-one patients scheduled to undergo upper or lower abdominal surgical procedures were allocated at random to one of seven treatment groups: in the recovery room they were to receive oxygen via a 40% Ventimask with 10 litres/minute oxygen flow, or via either a Hudson mask or a nasal cannula with 3, 6 or 9 litres/minute oxygen flow. The 40% Ventimask gave the most consistent, satisfactory postoperative values of PaO2 but the much cheaper nasal cannula at 6 or 9 litres/minute was generally adequate in conscious patients. The performance of the intermediately priced Hudson mask was similar to that of the nasal cannula at these flows. The unconscious state was associated with a 45% lower PaO2 than the rousable or awake states. Differences between the treatments with regard to postoperative PaCO2 were small and non-significant. The nasal cannula with 6 litres/minute humidified oxygen flow is recommended for routine treatment, and the Ventimask for unconscious patients.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3128137     DOI: 10.1111/j.1365-2044.1988.tb05483.x

Source DB:  PubMed          Journal:  Anaesthesia        ISSN: 0003-2409            Impact factor:   6.955


  3 in total

Review 1.  Hypoxaemia in adults in the post-anaesthesia care unit.

Authors:  M D Daley; P H Norman; M E Colmenares; A N Sandler
Journal:  Can J Anaesth       Date:  1991-09       Impact factor: 5.063

2.  Capnographic Analysis of Minimum Mandatory Flow Rate for Hudson Face Mask: A Randomized Double-blind Study.

Authors:  Pranjali Kurhekar; T Krishna Prasad; Buddhan Rajarathinam; M S Raghuraman
Journal:  Anesth Essays Res       Date:  2017 Apr-Jun

3.  The value of high-flow nasal cannula oxygen therapy after extubation in patients with acute respiratory failure.

Authors:  Hong-Zhuan Song; Juan-Xian Gu; Hui-Qing Xiu; Wei Cui; Gen-Sheng Zhang
Journal:  Clinics (Sao Paulo)       Date:  2017-10       Impact factor: 2.365

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.